Diagnamed Holdings Corp. - DGNMF STOCK NEWS

DiagnaMed Holdings Corp., a healthcare technology firm focused on brain health using AI, has announced a private placement offering of up to $650,000. This offering, led by EMD Financial, is priced at $0.04 per unit. Each unit consists of one common share and one warrant, allowing acquisition of an additional share at $0.05 within 36 months. The proceeds will fund the BRAIN AGE® Brain Health AI Platform and general purposes. The offering is open to most Canadian provinces and closes around June 10, 2024, pending regulatory approvals.

DiagnaMed Holdings Corp. is set to commercialize its BRAIN AGE® Brain Health AI Platform, an innovative solution that estimates brain age and provides a brain health score.

This platform aims to target the global digital brain health market, projected to reach USD 405.53 billion by 2031. BRAIN AGE® assesses brain health using a low-cost EEG headset and a proprietary machine-learning model, making it accessible and affordable for large-scale use.

The platform is clinically validated through studies at Drexel University and the University of Miami, showing its potential in detecting cognitive decline and optimizing brain performance.

BRAIN AGE® targets diverse users, including healthy individuals, athletes, and neurodegenerative patients, with potential applications in up to 10,000 North American clinics. The platform's goal is to empower individuals and healthcare professionals to improve brain health through personalized diagnostics and interventions.

DiagnaMed announced a clinical validation milestone for its BRAIN AGE® Brain Health AI Platform with a peer-reviewed paper. The platform offers a unique solution for estimating brain age and providing a brain health score, as detailed in a publication in Frontiers in Neuroergonomics. This achievement marks a important step for the company in bringing its innovative AI solution to a wider audience, with the CEO highlighting the potential impact on brain health improvement for millions of users.

DiagnaMed, a healthcare technology company, launches BRAIN AGE® Brain Health AI in Canada, offering a brain health and wellness AI solution for clinics. The Government of Ontario's investment in brain health initiatives could synergize with BRAIN AGE® to enhance brain health outcomes in the country.

DiagnaMed Holdings Corp. expands its CERVAI™ Brain Health AI Platform by adding Drexel University as a test launch site. The platform estimates BRAIN AGE® and provides a brain health score, aiming to detect potential brain health issues and cognitive decline.

DiagnaMed Holdings Corp. receives approval for trademark registration of its BRAIN AGE® brand for commercial use in Canada, as part of its CERVAI™ Brain Health AI Platform. The company is expanding its commercial initiatives and collaborating with leading research hospitals in Canada. The CERVAI™ Brain Health commercial pilot program is available to clinics in Canada and the U.S.

DiagnaMed Holdings Corp. announces potential $150,000 in non-dilutive funding support through IPON and IP Assist Programs to strengthen its intellectual property portfolio for commercializing CERVAI™ Brain Health AI solution.

DiagnaMed Holdings Corp. has been accepted into the HEALTHI program to accelerate clinical research and commercialization efforts in Canada for its CERVAI™ Brain Health AI Platform. The program aims to establish relationships with leading clinicians and hospital facilities to improve brain health assessment and intervention. CERVAI™ combines Brain Age™ Estimation and Brain Health Assessment tools to identify potential brain health issues, offering personalized diagnostics and interventions.

DiagnaMed Holdings Corp. announces the test launch of CERVAI™, a consumer brain health and wellness AI solution, at the University of Miami Comprehensive Center for Brain Health. The platform assesses brain health through a Resilience Index, Vulnerability Index, and Number-Symbol Coding Task, showing promising results in detecting Alzheimer's disease risk.